Patents Assigned to FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
  • Patent number: 11814650
    Abstract: Method for expanding stemness and differentiation potential of pluripotent cells. The invention is based on the finding that increasing micro RNA-203 levels in induced pluripotent stem (iPSCs) or embryonic stem (ESCs) cells improves the quality cell fate potential and ability of these cells to differentiate into multiple cell lineages and to reach further maturation properties without interfering with their self-renewal properties. This effect is mediated through the mi R-203-dependent control of de novo DNA methyltransferases Dnmt3a and Dnmt3b, which in turn regulate the methylation landscape of pluripotent cells. The effect can be achieved by overexpression of micro RNA-203 or by adding micro RNA-203 or analogues thereof to the cell culture medium and can be observed using a variety of cellular and in vivo models.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 14, 2023
    Assignee: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO)
    Inventors: Marcos Malumbres, Maria Salazar-Roa, Marianna Trakala, Mónica Alvarez-Fernandez
  • Patent number: 11261434
    Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 1, 2022
    Assignees: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO), Universität Autónoma de Barcelona
    Inventors: Maria Antonia Blasco Marhuenda, Bruno Bernardes De Jesus, Christian Baer, Rosa María Serrano Ruiz, Fàtima Bosch I Tubert, Eduard Ayuso, Ivan Formentini, Maria Bobadilla, Jacques Mizrahi
  • Patent number: 10208056
    Abstract: There is provided compounds of formula I, wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 19, 2019
    Assignee: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
    Inventors: Joaquín Pastor Fernández, Sonia Martínez González, Carmen Blanco-Aparicio, Ana Isabel Hernández Higueras, Cristina Ana Gómez De La Oliva, Virginia Rivero Buceta, Rosario Concepción Riesco Fagundo